MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment... ((Combined useof genomic prognostic and t...)

MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions

Date:5/30/2008

(Combined use of genomic prognostic and treatment response predictors in breast cancer) will be presented by Lajos Pusztai, M.D., Ph.D., associate professor of medicine at M.D. Anderson Cancer Center on June 2 at 8:00 am/12 noon.

"These findings are exciting as they suggest that different predictive tests that evaluate the risk of recurrence and therapeutic response can be used conjunctively on a single tumor sample to help physicians gain a clearer picture of a patient's treatment needs," Dr. Pusztai said. "The information gained from multiple predictive tests can be used to help physicians make more personalized decisions related to patient management. It may also be useful in helping identify additional areas for research, such as determining the best course of treatment for patients who are identified as being at high risk for breast cancer recurrence and also likely to not respond to certain treatments."

The second study (abstract #6575) was a prospective trial to assess the clinical implementation of MammaPrint in 15 community hospitals in The Netherlands. Of 427 MammaPrint gene profiles obtained from 812 patients with node-negative breast cancer, 30% of the results were discordant with the Dutch treatment guidelines. For example, some patients categorized as high risk for cancer recurrence using MammaPrint had been previously identified as low risk using the guidelines. In 54% of the discordant cases, the course of treatment was changed. The abstract (Implementation assessment of the 70-gene prognosis signature for breast cancer diagnostics) will be presented by Valesca Retel, Ph.D. student at the Netherlands Cancer Institute, on June 1 at 8:00 am.

"MammaPrint provides important information that physicians don't otherwise get through prognostic guidelines. More importantly, physicians in community-based hospitals in this trial highly valued the addition of the information provided by MammaPrint as benefiting patient management," Dr. van
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
4. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
5. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
6. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
7. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
8. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
9. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
10. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
11. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer

Post Your Comments:

MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment...((Combined useof genomic prognostic and t...)